Gilead Sciences (GILD) Revenue — Quarter Ended Mar 31, 2024
Gilead Sciences reported a decline in revenue for the first quarter of fiscal 2024 compared to the immediately preceding quarter, but an increase compared to the same quarter one year earlier.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Gilead Sciences reported a decline in revenue for the first quarter of fiscal 2024 compared to the immediately preceding quarter, but an increase compared to the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$6.7B
Revenue reported for this quarter.
Quarter-over-quarter
-6.0%
Change from the immediately preceding quarter.
Year-over-year
+5.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$27.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $6.6B | +5.4% |
| Sep 30, 2023 | $7.1B | +0.1% |
| Dec 31, 2023 | $7.1B | -3.7% |
| Mar 31, 2024 | $6.7B | +5.3% |
Revenue performance
Revenue for the quarter moved lower from the prior quarter, yet remained above the level achieved in the same quarter of the prior year.
Quarterly comparison
The sequential decline reflects a reversal from the prior quarter's trend, while the year-over-year gain marks an improvement over the same period last year.
What to watch
Monitor whether the sequential revenue decline extends into the next quarter.